Headache,Raynaud’s syndrome and serotonin receptor agonists in systemic lupus erythematosus

Abstract

There are potential concerns regarding serotonin receptor agonists in SLE patients with migraine, particularly patients with concomitant Raynaud’s syndrome. We estimated the prevalence of lupusrelated headache and Raynaud’s syndrome in the Montreal General Hospital SLE clinic cohort and evaluated the relationship between these two variables in multivariable logistic regression models, controlling for age, sex, race, SLE duration and the presence of lupus anticoagulant and antibodies to cardiolipin and beta2 glycoprotein I. We also assessed, through chart review in those individuals with both Raynaud’s syndrome and migraine, a history of serotonin receptor agonist use, and any associated worsening vasospasm. Based on Systemic Lupus Activity Measure (SLAM) scores, the cumulative incidence of lupus-related headache in our sample (n 391) was 46.1%; the prevalence of Raynaud’s syndrome was 49.4%. The adjusted odds ratio (OR) for lupus-related headache and Raynaud’s syndrome was 1.7 (95% CI 1.1, 2.5). In addition, there was a strong independent relationship between headache and anti-beta2 glycoprotein I antibodies (adjusted OR 5.6 [95% CI 1.8, 17.0]). The data from our chart review suggest that careful use of serotonin receptor agonists in patients with both Raynaud’s syndrome and migraines may be undertaken, although caution would necessitate that these agents not be used in individuals with very severe Raynaud’s (eg, digital ulcerations, and so on).

Keywords

headache Raynaud’s syndrome systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Markus HS , Hopkinson N . Migraine and headache in systemic lupus erythematosus and their relationship with antibodies against phospholipids . J Neurol 1992; 239: 39–42 .

Montalban J , Cervera R , Font J et al. Lack of association between anticardiolipin antibodies and migraine in systemic lupus erythematosus . Neurology 1992; 42: 681–682 .

Whitelaw D , Hugo F , Spangenberg J , Rickman R . Headaches in patients with systemic lupus erythematosus: a comparative study . Lupus 2004; 13: 501–505 .

Ferrari MD , Roon KI , Lipton RB , Goadsby PJ . Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials . The Lancet 2001; 358: 1668–1675 .

Koh KK , Roe IH , Lee MM , Cho SK , Kim SS . Variant angina complicating ergot therapy of migraine . Chest 1994; 105: 1259–1260 .

Sfikakis P , Mitsikostas D , Manoussakis M , Foukaneli D , Moutsopoulos H . Headache in systemic lupus erythematosus: a controlled study . Br J Rheumatology 1998; 37: 300–303 .

Block JA , Sequeira W . Raynaud’s phenomenon . The Lancet 2001; 357: 2042–2048 .

Zahavi I , Chagnac A , Hering R , Davidovich S , Kuritzky A . Prevalence of Raynaud’s phenomenon in patients with migraine . Arch Intern Med 1984; 144: 742–744 .

Appenzeller S , Costallat LTL . Clinical implications of migraine in systemic lupus erythematosus: relation to cumulative organ damage . Cephalalgia 2004; 24: 1024–1030 .

10.

Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1998; 41: 751-751 .

11.

Tan EM , Cohen AS , Fries JF , Masi AT , McShane DJ , Rothfield NF . The 1982 revised criteria for the classification of SLE . Arthritis and Rheumatism 1982; 25: 1271–1277 .

12.

Liang MH , Socher SA , Roberts WN , Esdaile JM . Measurement of systemic lupus erythematosus activity in clinical research . Arthritis and Rheumatism 1988; 31: 817–825 .

13.

Wilson WA , Gharavi AE , Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome – Report of an international workshop . Arthritis and Rheumatism 1999; 42: 1309–1311 .

14.

Weder-Cisneros N , Tellez-Zenteno J , Cardiel M et al. Prevalence and factors associated with headache in patients with systemic lupus erythematosus . Cephalalgia 2004; 24: 1031–1044 .

15.

Levine JS , Subang R , Koh JS , Rauch J . Induction of anti-phospholipid autoantibodies by beta 2-glycoprotein I bound to apoptotic thymocytes . Journal of Autoimmunity 1998; 11: 413–424 .

16.

Rauch J , Janoff AS . Phospholipid in the hexagonal II phase is immunogenic: evidence for immunorecognition of nonbilayer lipid phases in vivo . Proceedings of the National Academy of Sciences of the United States of America 1990; 87: 4112–4114 .

17.

Isenberg D , Meyrick-Thomas D , Snaith M , McKeran R , Royston J . A study of migraine in systemic lupus erythematosus . Ann Rheum Dis 1982; 41: 30–32 .

18.

Hottenga JJ , Vanmolkot KRJ , Kors EE et al. The 3p21.1-p21.3 hereditary vascular retinopathy locus increases the risk for Raynaud’s phenomenon and migraine . Cephalalgia 2005; 25: 1168–1172 .

19.

Williams F , Cherkas L , Spector T , MacGregor A . A common genetic factor underlies hypertension and other cardiovascular disorders . BMC Cardiovasc Discord 2004; 4: 20-20 .

20.

Nakamura Y , Shinozaki N , Hirasawa M et al. Prevalence of migraine and Raynaud’s phenomenon in Japanese patients with vasospastic angina . Jpn Circ J 2000; 64: 239–242 .

21.

Voulgari PV , Alamanos Y , Papazisi D , Christou K , Papanikolaou C , Drosos AA . Prevalence of Raynaud’s phenomenon in a healthy Greek population . Ann Rheum Dis 2000; 59: 206–210 .

22.

O’Keeffe ST , Tsapatsaris NP , Beetham WP Jr. Association between Raynaud’s phenomenon and migraine in a random population of hospital employees . J Rheumatol 1993; 20: 1187–1188 .

23.

Hawker G , Gabriel S , Bombardier C , Goldsmith C , Caron D , Gladman D . A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus . J Rheumatol 1993; 20: 657–660 .

24.

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes . Arthritis Rheum 1999; 42: 599–608 .

25.

Coleiro B , Marshall SE , Denton CP et al. Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine . Rheumatology 2001; 40: 1038–1043 .